Use of Oral Topiramate to Promote Smoking Abstinence Among Alcohol-Dependent Smokers

Johnson, Bankole A.; Ait-Daoud, Nassima; Akhtar, Fatema Z.; Javors, Martin A.

doi:10.1001/archinte.165.14.1600

Cited by 109 publications

(104 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Topiramate, a sulfamate-substituted fructopyranose derivative, has been shown to be efficacious in the treatment of both alcohol (Johnson et al, 2003) and cocaine (Kampman et al, 2004) dependence, and to promote smoking cessation among alcohol-dependent individuals who smoke (Johnson et al, 2005a). These therapeutic effects have been attributed to its hypothesized potential to reduce levels of cortico-mesolimbic dopamine, the primary neurochemical substrate for the acquisition and maintenance of drug-seeking behavior for the majority of abused drugs including alcohol, cocaine, tobacco, and amphetamines (Hemby et al, 1997;Wise, 1998).…”

Section: Introductionmentioning

confidence: 99%

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

Methamphetamine-dependent individuals often cite the need to maintain enhanced cognitive performance and attention as a reason for continuing or relapsing to drug-taking. Further, methamphetamine addicts might not comply with taking a potentially therapeutic medication if it had a profound effect on these cognitive processes. Topiramate, a sulfamate-substituted fructopyranose derivative, has been suggested as a putative therapeutic medication for treating methamphetamine dependence. Examination of topiramate's effects on cognitive performance and attention is a clinically and scientifically important component of understanding its potential therapeutic profile. In 10 male and female individuals who met DSM-IV criteria for methamphetamine dependence, we examined the effects of low (50 mg b.i.d.)-and high (100 mg b.i.d.)-dose topiramate -in both the presence and absence of low (15 mg)-and high (30 mg)-dose intravenous methamphetamine -on cognitive performance, attention, and concentration on the rapid visual information processing task and the digit symbol substitution test. Intravenous methamphetamine enhanced cognitive performance, attention, and concentration among recently withdrawn methamphetamine addicts -an effect that hitherto had not been well characterized. Topiramate's cognitive effects were mixed and rather paradoxical, with a tendency to improve attention and concentration both alone and in the presence of methamphetamine while worsening psychomotor retardation. No deleterious interaction occurred between topiramate and methamphetamine on any of these cognitive processes. While clinical studies with topiramate should Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. NIH Public Access

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Johnson

Roache

Ait-Daoud

et al. 2007

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…9 Initially, complex epilepsy was the only indication for treatment with topiramate. Recently it has been suggested that topiramate may be useful in the treatment of obesity [10][11][12][13][14][15] , eating disorders [16][17][18][19][20] , migraine [21][22][23][24][25][26][27][28][29][30][31] , bipolar disorders [32][33][34][35] , other psychiatric disorders [36][37][38][39][40][41][42] , alcohol dependence [43][44][45][46][47] and other addictive disorders 48 . Also the drug is more frequently used in the management of childhood epilepsy [49][50][51] .…”

Section: Introductionmentioning

confidence: 99%

Retinal function and histopathology in rabbits treated with Topiramate

et al. 2006

View full text Add to dashboard Cite

Methods: Six rabbits were treated with a daily oral dose of topiramate orally during a period of eight months. Six rabbits receiving water served as controls. Blood samples were analyzed for determination of topiramate serum levels in order to ensure successful drug exposition.Standardized full-field electroretinograms (ERGs) were performed before treatment and then at 2, 3 and 8 months during the treatment period. After terminating treatment the rabbits were sacrificed and the morphology of the sectioned retina was studied. The retinal dysfunction and the morphological changes indicate that topiramat may damage the retina, similarly to vigabatrin (another anti-epileptic drug).

show abstract

“…Topiramate-treated subjects were more likely to be abstinent from cocaine compared to placebo-treated subjects (Kampman et al, 2004), suggesting that topiramate may be effective for the treatment of cocaine dependence. In another clinical trial examining the effects of topiramate in alcohol dependent subjects, those assigned to topiramate were more likely to quit smoking than those assigned to placebo (19.4 vs 6.9% at week 12) (Johnson et al, 2005). These preliminary findings concerning the potential use of topiramate for the treatment of cocaine and nicotine dependence are encouraging.…”

Section: Introductionmentioning

confidence: 89%

Topiramate does not alter nicotine or cocaine discrimination in rats

Foll

Justinová²,

Wertheim³

et al. 2008

Behavioural Pharmacology

View full text Add to dashboard Cite

The effects of topiramate were evaluated in two groups of rats trained to discriminate administration of either 0.4 mg/kg nicotine or 10 mg/kg cocaine from administration of saline under a fixed-ratio 10 schedule of food delivery. Topiramate (1−60 mg/kg, i.p.) did not produce any nicotine-or cocainelike discriminative effects by itself and did not produce any shift in the dose-response curves for nicotine or cocaine discrimination. Thus, the ability to discriminate nicotine's or cocaine's effects does not appear to be altered by topiramate administration. Also, topiramate, given either alone or in combination with nicotine or cocaine, did not depress rates of responding. These experiments indicate that topiramate does not enhance or reduce the ability of rats to discriminate the effects of nicotine or cocaine.

show abstract

Use of Oral Topiramate to Promote Smoking Abstinence Among Alcohol-Dependent Smokers

Abstract: In this trial, topiramate (up to 300 mg/d) showed potential as a safe and promising medication for the treatment of cigarette smoking in alcohol-dependent individuals.

Cited by 109 publications

References 30 publications

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals

Retinal function and histopathology in rabbits treated with Topiramate

Topiramate does not alter nicotine or cocaine discrimination in rats

Contact Info

Product

Resources

About